title: Quinolinic acid: effects on brain catecholamine and c-AMP content during L-dopa and reserpine administration.
abstract: The catecholamine content in rat brain tissue was determined following the administration of quinolinic acid alone or combined either with L-dopa and decarboxylase inhibitor or reserpine. Quinolinic acid alone decreased the levels of dopamine and noradrenaline, as well as those of c-AMP, and increased those of adrenaline. Treatment with L-dopa/decarboxylase inhibitor reversed the suppressing effect of quinolinic acid on dopamine, but not on noradrenaline. Reserpine alone depleted the contents of dopamine, noradrenaline and adrenaline. It could be concluded from the effects of quinolinic acid and reserpine given together that quinolinic acid suppresses the depletion of amines induced by reserpine. It has been demonstrated that quinolinic acid leads to injuries of nerve-cell bodies in pars compacta of the substantia nigra and in the striatum. Quinolinic acid is a natural metabolite of tryptophan, normally occurring in the liver, kidney and brain (Wolfensberger et al. 1983; Moroni et al. 1984). This compound exhibits convulsant and neuron excitant properties (Stone et al. 1987). It induces a selective pattern of neuronal degeneration both at the site of intracerebral injection (Schwarcz et al. 1983; Stone et al. 1987) and after general (intracardiac) administration (Beskid and Markiewicz 1988). The ability of quinolinic acid to produce neurotoxicity was greater in the striatum than in other parts of the brain. This prompted us to study catecholamine and c-AMP levels in rat brain tissue following quinolinic acid and L-dopa administration, as well as the influence of reserpine on quinolinic acid action.
authors.affiliation: Medical Centre of Postgraduate Education, Department of Cell Pathophysiology, Warsaw, Poland.
authors.forename: M
authors.initials: M
authors.lastname: Beskid
authors.forename: L
authors.initials: L
authors.lastname: Finkiewicz-Murawiejska
mesh_terms: D000818:Animals; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D002395:Catecholamines / Q000378:metabolism*; D000242:Cyclic AMP / Q000378:metabolism*; D004298:Dopamine / Q000378:metabolism; D004837:Epinephrine / Q000378:metabolism; D007980:Levodopa / Q000494:pharmacology; D008297:Male; D009638:Norepinephrine / Q000378:metabolism; D017378:Quinolinic Acid; D011805:Quinolinic Acids / Q000494:pharmacology*; D051381:Rats; D012110:Reserpine / Q000494:pharmacology
chemical_list: D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D002395:Catecholamines; D011805:Quinolinic Acids; D007980:Levodopa; D012110:Reserpine; D000242:Cyclic AMP; D017378:Quinolinic Acid; D004298:Dopamine; D009638:Norepinephrine; D004837:Epinephrine